Center for Human Genome Variation

NEJM last week published a quartet of perspectives offering a range of opinions on the value of GWAS and DTC testing, but two critical articles in particular caused financial analysts and the American news media to conclude that the perspectives could negatively impact companies that provide tools for these studies.

Direct-to-consumer genetic testing companies have based their products on what scientists have accomplished, but the caveat is that the science is still in its early days.